PFS curves for all 154 patients with early-stage MF based on the 3-miRNA classifier stratified by clinical prognostic factors and clinical characteristics. Treatment is defined by use of skin-directed therapies (topical corticosteroids, phototherapy, or nitrogen mustard) upon diagnosis. No patients received systemic therapies. CLIPi was categorized as CLIPi < 3, including patients with CLIPi group 1 = low risk (0-1 risk factors) and CLIPi group 2 = intermediate risk (2 risk factors); and CLIPi = 3, including patients with CLIPi group 3 = high risk (3-5 risk factors).¹² P values were calculated using the log-rank test.